Handa Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,617	830.67	1,106	197.68	29.24	28.86
Revenue Growth (YoY)	71.59%	-24.92%	459.66%	576.16%	1.30%	-65.67%
Cost of Revenue	229.95	1.17	1.3	18.71	1.46	1.42
Gross Profit	1,387	829.5	1,105	178.97	27.77	27.44
Selling, General & Admin	160.4	119.54	144.25	87.31	72.67	70.87
Research & Development	360.38	291.91	267.34	179.78	208.99	274.04
Operating Expenses	520.78	411.44	411.59	267.09	281.66	344.92
Operating Income	866.7	418.06	693.43	-88.12	-253.88	-317.48
Interest Expense	-0.93	-0.49	-0.22	-0.28	-0.23	-0.45
Interest & Investment Income	52.68	57.06	18.16	0.5	0.29	2.99
Earnings From Equity Investments	0.82	-1.81	2.37	-	-	-
Currency Exchange Gain (Loss)	-32.59	26.9	1.71	44.02	-7.27	-14.31
Other Non Operating Income (Expenses)	-29.83	-20.36	0.03	0.73	0.27	13.3
EBT Excluding Unusual Items	856.85	479.36	715.47	-43.15	-260.82	-315.95
Gain (Loss) on Sale of Assets	-0.16	-0.19	4.61	-0	0.02	-0
Asset Writedown	-	-	-	-	-	-4.5
Legal Settlements	-	-	72.41	-	-	-
Pretax Income	856.69	479.17	792.49	-43.15	-260.8	-320.45
Income Tax Expense	173.53	6.43	65.6	-3.14	-13.13	-38.34
Net Income	683.16	472.74	726.89	-40.01	-247.67	-282.1
Net Income to Common	683.16	472.74	726.89	-40.01	-247.67	-282.1
Net Income Growth	50.71%	-34.96%	-	-	-	-
Shares Outstanding (Basic)	150	140	134	126	118	116
Shares Outstanding (Diluted)	151	141	135	126	118	116
Shares Change (YoY)	6.72%	4.73%	7.29%	6.65%	1.87%	5.35%
EPS (Basic)	4.56	3.37	5.41	-0.32	-2.10	-2.44
EPS (Diluted)	4.53	3.35	5.40	-0.32	-2.10	-2.44
EPS Growth	40.86%	-37.96%	-	-	-	-
Free Cash Flow	175.65	489.84	667.42	-212.21	-184.82	-315.88
Free Cash Flow Per Share	1.17	3.47	4.95	-1.69	-1.57	-2.73
Dividend Per Share	1.500	1.500	1.000	-	-	-
Dividend Growth	50.00%	50.00%	-	-	-	-
Gross Margin	85.78%	99.86%	99.88%	90.53%	95.00%	95.07%
Operating Margin	53.59%	50.33%	62.68%	-44.58%	-868.42%	-1100.10%
Profit Margin	42.24%	56.91%	65.70%	-20.24%	-847.17%	-977.52%
Free Cash Flow Margin	10.86%	58.97%	60.33%	-107.35%	-632.19%	-1094.57%
EBITDA	981.06	421.12	698.48	-81.3	-245.05	-309.06
EBITDA Margin	60.66%	50.70%	63.14%	-41.13%	-	-
D&A For EBITDA	114.36	3.06	5.06	6.82	8.83	8.42
EBIT	866.7	418.06	693.43	-88.12	-253.88	-317.48
EBIT Margin	53.59%	50.33%	62.68%	-44.58%	-	-
Effective Tax Rate	20.26%	1.34%	8.28%	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.